DUBLIN – Apogenix AG plans to file late next year for conditional approval in Europe for its CD95 antagonist, asunercept (formerly APG-101), following a review of a phase II trial in recurrent glioblastoma, which uncovered a five-year overall survival rate of 7 percent for patients who received the drug in combination with radiotherapy. While that may not seem an overly dramatic efficacy signal, it is, by some distance, superior to the 0 percent rate for patients in the control group, who received radiotherapy only.